Blood Cancer Drug Discoveries: what the future holds

Date: April 22, 2008
Pages: 245
Price:
US$ 2,265.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BC4E64A0B4DEN
Leaflet:

Download PDF Leaflet

Blood Cancer Drug Discoveries: what the future holds
The market for blood cancer drugs will almost double by 2012 at an average year-on-year growth rate of 15%. What are the current and new products which will drive this growth and which are the companies to watch?

The size of the blood cancer market has expanded dramatically in recent years. Historically, its component disorders have been treated with combinations of radiotherapy and conventional chemotherapy, with the vast majority of agents being off-patent and having low overall market values.

However, in recent years the launch of several new products – and in particular Novartis’ Gleevec/Glivec and Genentech/Roche’s Rituxan/Mabthera – has transformed the sales dynamic dramatically. These new targeted therapies have been the mainstay of sales growth in the past decade, and now form the largest component of the market in value terms.

There are two key factors behind this effect: firstly the new targeted agents have led to an improvement in survival rates (which, in the case of chronic myeloid leukaemia, has led to large increases in prevalence), and secondly to their premium pricing, relative to the low-priced generic chemotherapies they are replacing.

Small market, big value

We estimate that although the blood cancers only represent 7% of cancer patient numbers, they represented up to 25% of the oncology market (excluding supportive care) in value terms in 2006.

Unmet clinical need

We believe that considerable further opportunity for growth in the blood cancer market. In each of the major therapy areas, there remains sizeable unmet medical need, giving rise to substantial sales potential for successful products. Additionally, in all therapy areas, conventional chemotherapy is used in some – if not all – patients, and there is a need for new agents with better tolerability.

Research continues to grow the sector

A range of new agents is in development for the treatment of blood cancers – including agents with established mechanisms of action, but with improved tolerability or efficacy – and also novel mechanisms of action. Of these new agents in development, we highlight the HDAC inhibitors and Hsp90 inhibitors as being among the most interesting, though much development remains in the early stages.

Among the products evaluated & forecast

Chronic lymphocytic leukaemia
  Rituxan
  ofatumumab
  lumiliximab
  Revlimid
  Treanda
Chronic myeloid leukaemia
  Gleevec
  Sprycel
  Tasigna
  bosutinib
  panobinostat
Acute myeloid leukaemia
  Clolar
  Cloretazine
  Dacogen
  Xanafide
  midostaurin
Multiple myeloma
  Revlimid
  Velcade
Non Hodgkin’s lymphoma
  Rituxan
  Pixantrone
  Revlimid
  ofatumumab
  Velcade

Questions answered

What is the prevalence and incidence of chronic myeloid leukaemia and how might this change by 2012?

Will Celgene be able to maintain its dominance in the multiple myeloma market in the face of Millennium’s Velcade?

What opportunities remain in the non-Hodgkin’s lymphoma market?
BLOOD CANCERS

  US incidence of blood cancers, 2007
Unmet Medical Need
New Agents In Development
  New mechanisms of action under investigation for the deveelopment of blood cancers:
  Monoclonal antibodies in development for treatment of blood cancers
Major Players
  2007
    Market share of players in the worldwide blood cancers market 2007.
  2012
    Market share of players in the worldwide blood cancers market 2012
Global Sales
  Estimatedand'forecast worldwide sales in the treatment ofbloodcancers(US$ millions)
Regional breakdown of blood cancer market by sales-2007 and 2012

CHRONIC LYMPHOCYTIC LEUKAEMIA

Background
Patient Statistics
  Patient model
     Estimated prevalence of CLLin major markets, 2005-2012
  Drug Growth Drivers
     Drug Growth Dampeners
  The Market
     Global Market
        Forecast CLL market growth (US$ millions)
     Major players
        Current drugs commonlyusedin the treatment ofCLL
        Major players in CLL by sales-2007
        Forecast major players in CLL by sales-2012
The Drugs
Current Drugs
  Selected responserates from studiesoffirstlinetreatmentof CLL:
Fludara
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast Fludara sales in CLL by region (US$ millions)
  Forecast Fludara sales in CLL by use (US$ millions)
  Competitor ratio analysis
Rituxan
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
     Forecast Rituxan sales in CLLby use (US$ millions)
     Forecast Rituxan sales in CLLby region (US$ millions)
  Competitor ratio analysis
Campath
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  ForecastCampathsalesinCLLbyuse(US$ millions)
  Competitor ratio analysis
Agents in Development
  Drugs in deveelopment for the treatment of CLL
  Agents in late stage deveelopment for CLL:
Treanda
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  ForecastTreanda sales in CLL (US$ millions)
  Competitor ratio analysis
Genasense
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Genasense in CLLefficacy summary:
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast Genasense sales in CLL by region (US$ millions):
  Forecast Genasense sales in CLL by use (US$ millions):
  Competitor ratio analysis
Ofatumumab
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast ofatumumab sales in CLLby region (US$millions):
  Forecast ofatumumab sales in CLLby use (US$millions):.
  Competitor ratio analysis
Alvocidib
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast alvocidib sales in CLL(US$ millions)
  Competitor ratio analysis
Lumliximab
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast lumiliximab sales in CLL(US$ millions)
  Competitor ratio analysis
Revlimid
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast RevlimidCLLsales by use (US$ millions):
  ForecastR&limidCLLsalesby region (US$ millions):
  Competitor ratio analysis 3

CHRONIC MYELOID LEUKAEMIA

Background
Patient Statistics
Tr  ends in US CML incidence:
  Estimated incidence in worldwide CML pr&alence:
Drug Growth Drivers
Drug Growth Dampeners
The Market
  Global market
     Forecast worldwide CML market (US$ millions)
  Major players-2007
     Major playersinCMLbysales-2007.
  Major players-2012
     Forecast major players in CLL by sales-2012
The Drugs
    CML treatment timeline:
  Current drugs
     Current drugs used in the treatment of CML
  Gleevec/Glivec
     Novelty/rationale for mechanism of action
     Proof of concept/clinical data
     IRISstudy:18-MonthResponseRatesDeterminedbylntent-to-TreatAnalysis
     Management/clinical expertise
     Competition within the marketplace/gaining share of voice
     Risks associated with developing a drug within a therapeutic class
     Filings and approval
     Sales forecasts and assumptions
     Forecast Gle&ec sales in CML (US$ millions)-excludes sales in GIST
     Competitor ratio analysis
Sprycel
      Novelty/rationale for mechanism of action
      Proof of concept/clinical data
      Management/clinical expertise
      Competition within the marketplace/gaining share of voice
   Risks associated with developing a drug within a therapeutic class
      Filings and approval
      Sales forecasts and assumptions
      Sprycel CMLsales(US$ millions):
      Competitor ratio analysis
   Tasigna
      Novelty/rationale for mechanism of action
      Proof of concept/clinical data
   Management/clinical expertise
      Competition within the marketplace/gaining share of voice
      Risks associated with developing a drug within a therapeutic class
      Filings and approval
      Sales forecasts and assumptions
      Tasigna CML sales forecast (US$ millions)
      Competitor ratio analysis
   Agents in Development
      Drugs in deveelopment for the treatment of CML:
      Agents in late stage deveelopmentforCML
   Bosutinib
      Novelty/rationale for mechanism of action
      Proof of concept/clinical data
      Management/clinical expertise
      Competition within the marketplace/gaining share of voice
      Risks associated with developing a drug within a therapeutic class
      Filings and approval
      Sales forecasts and assumptions
      Forecast bosutinib sales in CML (US$ millions)
      Competitor ratio analysis
   Panobinostat
      Novelty/rationale for mechanism of action
      Proof of concept/clinical data
      Management/clinical expertise
      Competition within the marketplace/gaining share of voice
      Risks associated with developing a drug within a therapeutic class
      Filings and approval
      Sales forecasts and assumptions
      Competitor ratio analysis
   MK-0457/VX680
      Novelty/rationale for mechanism of action
      Proof of concept/clinical data
      Management/clinical expertise
      Competition within the marketplace/gaining share of voice
      Risks associated with developing a drug within a therapeutic class
      Filings and approval
      Sales forecasts and assumptions
      Competitor ratio analysis

ACUTE MYELOID LEUKAEMIA

Background
  French-American-British (FAB) Classification ofAML
  WHOAMLdassification:
  Selected risk factors associated with AML
  Common chromosomal abnormalities in AML
Patient Statistics
  Forecast incidence of AML by region:
Drug Growth Drivers
Drug Growth Dampeners
The Market
  Global market
     ForecastworldwideadultAMLmarket.
  Major players-2007
  Major players - 2012
     Forecast major players in AML by sales-2012
The Drugs
  Treatment naive patients
  Relapsed & refractory AML
  Current drugs used in the treatment of AML:
  TherapeuticstrategiesinAMLand relapsed/refractory AML
Mylotarg
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Summary of response rates in Mylotarg studies:
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Competitor ratio analysis
Agents in Development
  Agents in late stage deveelopment for AML:
Clolar/Evoltra
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast sales of Qolar/Fvoltra in adultAML(US$ millions):
  Competitor ratio analysis
Cloretazine
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast sales of Cloretazine in AML(US$ millions)
  Competitor ratio analysis
Zarnestra
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Competitor ratio analysis
Dacogen
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  ForecastDacogen sales in adultAML(US$ millions)
  Competitor ratio analysis
lestaurtinib
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast lestaurtinib sales in AML(US$ millions) 776
  Competitor ratio analysis
midostaurin
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast midostaurin sales in AML(US$ millions)
  Competitor ratio analysis
tandutinib
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
Competitor ratio analysis
zosuquidar
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Competitor ratio analysis
Xanafide
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast Xanafide sales in AML(US$ millions)
  Competitor ratio analysis
Ceplene
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast Ceplene sales in AML (US$ millions)
  Competitor ratio analysis

MULTIPLE MYELOMA

Background
Patient Statistics
  Patient model
     Estimated pr&alence of multiple myeloma in selected markets.
Drug Growth Drivers
Drug Growth Dampeners
The Market
  Global market
     Forecast worldwide multiple myeloma market (US$ millions):
  Major players
  Major players in multiple myeloma by sales-2007
  Major players in multiple myeloma by sales-2012
  Current drugs used in the treatment of multiple myeloma:
The Drugs
Thalomid
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  ForecastThalomid sales in multiple myeloma (US$ millions)
  Competitor ratio analysis
Revlimid
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Data summary ofMM-009 and MM-010 studies:.
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Frontline myeloma comparison:
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Competitor ratio analysis
Velcade
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast Velcade sales in multiple myeloma (US$ millions)
  Competitor ratio analysis
Agents in Development
  Drugs in deveelopment for the treatment of multiple myeloma:
  Agents in late stage deveelopmentfor multiple myeloma: 75J
Tanespimycin
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast tanespimycin sales in relapsed/refractory multiple myeloma (US$ millions)
  Competitor ratio analysis
mapatumumab
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Competitor ratio analysis
Belinostat
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Competitor ratio analysis
Perifosine
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Competitor ratio analysis
Carfilzomib
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Competitor ratio analysis

NON HODGKIN'S LYMPHOMA

Background
  Frequency of NHL subtypes in adults:
1) B-cell CLL/small lymphocytic lymphoma
2) Marginal zone lymphoma
3) Lymphoplasmocytic lymphoma (Waldenstrom macroglobulinemia):
4) Follicular lymphoma:
1) Cutaneous T-cell lymphoma:
1) Diffuse large B-cell lymphoma (DLBCL):
2) Mantle cell lymphoma:
3) Burkitt lymphoma/Burkitt-like lymphoma:
4) Precursor B-cell leukaemia/lymphoma
1) Anaplastic large T/null-cell lymphoma:
2) Precursor T-lymphoblastic lymphoma/leukaemia:
3) Peripheral T-cell lymphomas:
Staging Systems
Patient Statistics
  Patient model
     Forecast NHL incidence andpr&alence (000s)
Drug Growth Drivers
Drug Growth Dampeners
The Market
Global market
  Forecast NHL market (excluding (TCL)-US$ millions
  ForecastCTCL market-US$ millions
Major players
  Current drugs commonly used in the treatment of NHL
  Major players in NHL by sales-2007
  Major players in NHL bysales -2012
The Drugs
  Low Grade or Indolent NHL
  Treatment options in indolent/low-grade NHL
  Intermediate-and high-grade lymphomas:
  T-cell lymphomas:
  Summaryofcommontherapies in NHL

MARKETED AGENTS FOR USE IN NHL

Rituxan
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Rituxan penetration rates, Q3-Q4 2005.
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast Rituxan sales in NHL indications by region (US$ millions)
  Forecast Rituxan sales in NHL indications by use (US$ millions)
  Competitor ratio analysis
Fludara
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast Fludara sales in NHL indications (US$ millions)
  Competitor ratio analysis
Bexxar
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast Bexxar sales (US$ millions):
  Competitor ratio analysis
Zevalin
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
xii ©Espicom Business Intelligence April 2008

Blood Cancer Drug Discoveries: what the future holds Table of Contents
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast Z&alin sales (US$ millions)
  Competitor ratio analysis

MARKETED AGENTS FOR CUTATENOUS T-CELL LYMPHOMA

Zolinza
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast Zolinza sales in CFCL(US$ millions)
  Competitor ratio analysis
Agents in Development
  DrugsindeveelopmentforthetreatmentofNHL 799
  Agents in late stage deveelopment for NHL
Treanda
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Treanda US sales forecasts in HHLindication (US$ millions)
  Competitor ratio analysis
ofatumumab
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Phase l/ll trial results summary:
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast sales ofofatumumab in HHLby region (US$ millions):
  Forecast sales ofofatumumab in HHLbyuse (US$ millions):
  Competitor ratio analysis
galiximab
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast galiximab sales in HHL(US$ millions)
  Competitor ratio analysis
April 2008 ©Espicom Business Intelligence xiii

Table of Contents Blood Cancer Drug Discoveries: what the future holds
pixantrone
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast pixantroneNHLsalesby region (US$ millions):
  Forecast pixantrone sales in NHLby use (US$ millions)
  Competitor ratio analysis
Revlimid
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Revlimid'sales forecasts in NHL(US$ millions)
  Competitor ratio analysis
Torisel
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  ForecastTorisel sales in MCL (US$ millions)
  Competitor ratio analysis
Velcade
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast Velcade sales in MCL(US$ millions)
  ForecastVelcade sales in follicularNHL (excludes MCL) byregion(US$ millions)
  ForecastVelcade sales in follicular NHL (excludes MCL) by use (US$ millions)
  Competitor ratio analysis
InotuzumabOzogamicin
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Competitor ratio analysis

AGENTS IN LATE STAGE DEVELOPMENT FOR CUTANEOUS T-CELL LYMPHOMA

Zanliumumab
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast sales ofzanolimumab in CTCL(US$ millions)
  Competitor ratio analysis
belinostat
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast sales ofbelinostatin(JCL(US$ millions)
  Competitor ratio analysis
Fodosine
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Forecast sales of Fodosine in CFCL(US$ millions)
  Competitor ratio analysis
Epratuzumab
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Competitor ratio analysis
enzastaurin
  Novelty/rationale for mechanism of action
  Proof of concept/clinical data
  Management/clinical expertise
  Competition within the marketplace/gaining share of voice
  Risks associated with developing a drug within a therapeutic class
  Filings and approval
  Sales forecasts and assumptions
  Competitor ratio analysis

CRA ANALYSIS: AML

CRAsummary

CRA ANALYSIS: CML

CRAsummary 238

CRA ANALYSIS: CLL

CRA ANALYSIS: MULTIPLE MYELOMA

CRASummary

CRA ANALYSIS: NHL

CRA analysis-NHL
CRA analysis-NHL (continued).. .includes CTCL

ACRONYMS
Skip to top


Breast Cancer Drug Discoveries: What the Future Holds US$ 3,145.00 Aug, 2011 · 382 pages
Prostate Cancer Drug Discoveries: What the Future Holds US$ 2,265.00 Nov, 2009 · 160 pages
Gastric Cancer Drug Discoveries: what the future holds US$ 2,615.00 Mar, 2011 · 158 pages
Obesity Drug Discoveries: what the future holds US$ 1,740.00 Aug, 2007 · 116 pages

Ask Your Question

Blood Cancer Drug Discoveries: what the future holds
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: